Skip to main content
  • Clinical
      |Clinical
    • Acute Coronary Syndromes
    • Cardiac Surgery
    • Covid-19
    • Heart Failure
    • Heart Health
    • Heart Rhythm
    • Hypertension
    • Interventional Cardiology
    • Mitral Valve
    • Pharmaceutics
    • Structural Heart Disease
    • TAVR
    • Tricuspid Valve
    • Vascular & Endovascular
  • Management
      |Management
    • Chest Pain Guidelines
    • Compensation
    • Economics
    • Education & Training
    • Legal News
    • Patient Care
    • Policy & Regulations
    • Professional Associations
    • Quality
    • Revenue
    • Staffing
  • Technology
      |Technology
    • AI
    • Cardiac Imaging
    • Cath Lab
    • CT
    • CVIS
    • ECG
    • Echo
    • EP Lab
    • Informatics
    • MRI
    • Nuclear Cardiology
    • Remote Monitoring
  • Videos
  • Conferences
      |Conferences
    • ACC
    • AHA
    • ASE
    • ASNC
    • ESC
    • EuroPCR
    • HFSA
    • HRS
    • SCAI
    • SCCT
    • SIIM
    • SNMMI
    • STS
    • TCT
    • VIVA
  • Custom Content
      |Custom Content
    • Experience Stories
    • Webinars & Videos
  • Subscribe
  • Forty Under 40 Award
      |Forty Under 40 Award
    • Class of 2026
    • Class of 2025

Search form

Home

Exclusive Coverage from ASE 2023
DRAFT 1 - Focus on hypertrophic cardiomyopathy: ASE HCM Forum coverage
Thursday, August 10, 2023
Link to Twitter Link to Facebook Link to Linkedin Link to Vimeo

Exclusive Coverage from ASE 2023

All eyes are on hypertrophic cardiomyopathy now that a drug treatment is in place

Ted Abraham, MD, explained why HCM has entered the limelight at recent cardiology conferences, including ASE 2023.

READ MORE >
Ted Abraham, MD, explains ASE efforts to increase HCM education and standardization of care. #HCM #ASE #ASE23 #ASE2023
Share on Twitter Share on Facebook Share on Linkedin

All eyes are on hypertrophic cardiomyopathy now that a drug treatment is in place

Share on Twitter Share on Facebook Share on Linkedin
Ted Abraham, MD, explains ASE efforts to increase HCM education and standardization of care. #HCM #ASE #ASE23 #ASE2023
Ted Abraham, MD, explained why HCM has entered the limelight at recent cardiology conferences, including ASE 2023.
READ MORE >

Surgery, interventional therapies still the best choice for many HCM patients

"You have to look at each patient and understand their goals," one HCM expert said in a new interview. 

READ MORE >
Video of Hari Naidu, MD, director of the Hypertrophic Cardiomyopathy Center of Excellence at Westchester Medical Center, explaining the role of alcohol septal ablation and surgical myectomy in the era of mavacamten. #HCM #ASE
Share on Twitter Share on Facebook Share on Linkedin

Surgery, interventional therapies still the best choice for many HCM patients

Share on Twitter Share on Facebook Share on Linkedin
Video of Hari Naidu, MD, director of the Hypertrophic Cardiomyopathy Center of Excellence at Westchester Medical Center, explaining the role of alcohol septal ablation and surgical myectomy in the era of mavacamten. #HCM #ASE
"You have to look at each patient and understand their goals," one HCM expert said in a new interview. 
READ MORE >

How medical imaging helps cardiologists treat hypertrophic cardiomyopathy

Hypertrophic cardiomyopathy expert Sherif F. Nagueh, MD, examined imaging's role in treating this serious condition. 

READ MORE >
HCM expert Sherif F. Nagueh, MD, FACC, FASE, professor of cardiology, Methodist DeBakey Heart and Vascular Center, explains the key points of HCM imaging. #ASE #HCM
Share on Twitter Share on Facebook Share on Linkedin

How medical imaging helps cardiologists treat hypertrophic cardiomyopathy

Share on Twitter Share on Facebook Share on Linkedin
HCM expert Sherif F. Nagueh, MD, FACC, FASE, professor of cardiology, Methodist DeBakey Heart and Vascular Center, explains the key points of HCM imaging. #ASE #HCM
Hypertrophic cardiomyopathy expert Sherif F. Nagueh, MD, examined imaging's role in treating this serious condition. 
READ MORE >

A surgeon's perspective on treating hypertrophic cardiomyopathy

Nicholas Smedira, MD, a cardiovascular surgeon with Cleveland Clinic, discusses septal myectomy and the need to improve overall HCM care with new standards and evidence-based guidelines.

READ MORE >
Photo of a surgical cardiac septal myectomy to treat hypertrophic cardiomyopathy (HCM). Nicholas Smedira MD discusses septal myectomy in HCM patients and the need for more detailed protocols for HCM care. #HCM #ASE #ASE2023 #myectomy
Share on Twitter Share on Facebook Share on Linkedin

A surgeon's perspective on treating hypertrophic cardiomyopathy

Share on Twitter Share on Facebook Share on Linkedin
Photo of a surgical cardiac septal myectomy to treat hypertrophic cardiomyopathy (HCM). Nicholas Smedira MD discusses septal myectomy in HCM patients and the need for more detailed protocols for HCM care. #HCM #ASE #ASE2023 #myectomy
Nicholas Smedira, MD, a cardiovascular surgeon with Cleveland Clinic, discusses septal myectomy and the need to improve overall HCM care with new standards and evidence-based guidelines.
READ MORE >

More consistency, standardization still needed when treating HCM

Anjali Owens, MD, discussed the past, present and future of hypertrophic cardiomyopathy care in the United States. "What we are aiming to do is develop a minimum standard for assessments of patients with HCM so they are getting properly diagnosed and managed," she explained. 

READ MORE >
Anjali Owens, MD, medical director, Center for Inherited Cardiac Disease, associate professor of medicine at the Hospital of the University of Pennsylvania, discusses the need for standardization in HCM care. #ASE #ASE23 #ASE2023 #HCM
Share on Twitter Share on Facebook Share on Linkedin

More consistency, standardization still needed when treating HCM

Share on Twitter Share on Facebook Share on Linkedin
Anjali Owens, MD, medical director, Center for Inherited Cardiac Disease, associate professor of medicine at the Hospital of the University of Pennsylvania, discusses the need for standardization in HCM care. #ASE #ASE23 #ASE2023 #HCM
Anjali Owens, MD, discussed the past, present and future of hypertrophic cardiomyopathy care in the United States. "What we are aiming to do is develop a minimum standard for assessments of patients with HCM so they are getting properly diagnosed and managed," she explained. 
READ MORE >

Hypertrophic Cardiomyopathy Association has helped advance HCM care

The Hypertrophic Cardiomyopathy Association (HCMA) has helped guide and advance HCM care not only for patients, but also for hospitals and physicians. 

READ MORE >
Clinical illustration showing the types of hypertrophic cardiomyopathy (HCM). Lisa Salberg, CEO of the Hypertrophic Cardiomyopathy Association (HCMA) explains how the group has helped improve HCM patient care. #HCM #Hypertrophiccardiomyopathy
Share on Twitter Share on Facebook Share on Linkedin

Hypertrophic Cardiomyopathy Association has helped advance HCM care

Share on Twitter Share on Facebook Share on Linkedin
Clinical illustration showing the types of hypertrophic cardiomyopathy (HCM). Lisa Salberg, CEO of the Hypertrophic Cardiomyopathy Association (HCMA) explains how the group has helped improve HCM patient care. #HCM #Hypertrophiccardiomyopathy
The Hypertrophic Cardiomyopathy Association (HCMA) has helped guide and advance HCM care not only for patients, but also for hospitals and physicians. 
READ MORE >

Exercise plays a key part in HCM management

Matthew Martinez, MD, detailed the many ways HCM care management is changing during an exclusive interview at ASE 2023.

READ MORE >
Matt Martinez, MD, Morristown Medical Center HCM program, explains how hypertrophic cardiomyopathy patient management is changing.
Share on Twitter Share on Facebook Share on Linkedin

Exercise plays a key part in HCM management

Share on Twitter Share on Facebook Share on Linkedin
Matt Martinez, MD, Morristown Medical Center HCM program, explains how hypertrophic cardiomyopathy patient management is changing.
Matthew Martinez, MD, detailed the many ways HCM care management is changing during an exclusive interview at ASE 2023.
READ MORE >

Why hypertrophic cardiomyopathy may be widely underdiagnosed

One expert believes the lack of standardization for how diagnostic imaging in conducted and reported has led to a major underdiagnosis of HCM.

READ MORE >
Hari Naidu, MD, explains that inconsistent diagnostic imaging and how it is reported has likely led to a major underdiagnosis of HCM. #ASE #ASE2023 #HCM
Share on Twitter Share on Facebook Share on Linkedin

Why hypertrophic cardiomyopathy may be widely underdiagnosed

Share on Twitter Share on Facebook Share on Linkedin
Hari Naidu, MD, explains that inconsistent diagnostic imaging and how it is reported has likely led to a major underdiagnosis of HCM. #ASE #ASE2023 #HCM
One expert believes the lack of standardization for how diagnostic imaging in conducted and reported has led to a major underdiagnosis of HCM.
READ MORE >

Innovate Healthcare thanks our partners for supporting our newsletters.
Sponsorship has no influence on editorial content.

Interested in reaching our audiences, contact our team

*|LIST:ADDRESSLINE|*

You received this email because you signed up for newsletters from Innovate Healthcare.
Change your preferences or unsubscribe here

Contact Us  |  Unsubscribe from all  |  Privacy Policy

© Innovate Healthcare, a TriMed Media brand
Innovate Healthcare

Recent Newsletters

Week in Review: TAVR vs. SAVR | FDA clears AI tech | Payment model confusion | Private equity & cardiology | Injuries after PCI
Heart surgery kits recalled | Sex-specific outcomes after TAVR & SAVR | A new risk calculator | FDA clears tricuspid valve
Thousands of heart surgery kits recalled | TAVR for AR linked to 'encouraging' data | Carotid IVL | Progress for new HCM drug
AI company founded by cardiologist makes big splash | Getting clinicians on the same page | Kidney injuries after PCI
Sweeping TAVR changes on the way | Pushing back against AI-powered prior authorization | FDA highlights recall after injuries
Cardiologists added to payment model by mistake | Sex-specific outcomes after TAVR & SAVR | FDA clears new AI software
Private equity unlikely to dominate cardiology | Cardiology opposes Medicare AI prior authorization | New AATS leaders

Pagination

    • Current page 1
    • Page 2
    • Page 3
    • Page 4
    • Page 5
    • Page 6
    • Page 7
    • Page 8
    • Page 9 …
    • Next page ››
    • Last page Last »
  • Home
  • News
  • Article Archive
  • Custom Content
  • Webinars
  • Press Releases
  • Content Studio
  • Advertising
  • Submit Press Release
  • Contact Us
  • Terms of Use
  • Privacy Policy
  • Cardiovascular Business
  • HealthExec
  • Radiology Business
 
© 2026 Innovate Healthcare | All Rights Reserved. | Terms of Use | Privacy Policy
 
Design by Adaptive Theme
Trimed Popup